Swedish Orphan Biovitrum AB (CHIX:SOBIS) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SOBIS Swedish Orphan Biovitrum AB CHIX:SOBIS
89 GF Score
Price kr437.10
GF Value kr371.59
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Swedish Orphan Biovitrum AB  (CHIX:SOBIs) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio Related Terms


Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.19 4.79 4.37 4.94 4.31

Swedish Orphan Biovitrum AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.21 4.05 4.48 5.27 5.97

CHIX:SOBIS vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio falls into.


CHIX:SOBIS
89GF Score
Swedish Orphan Biovitrum AB CHIX:SOBIS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Swedish Orphan Biovitrum AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Swedish Orphan Biovitrum AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=121.709/134.6100*134.6100
=121.709

Current CPI (Jun. 2026) = 134.6100.

Swedish Orphan Biovitrum AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 19.111 101.138 25.436
201612 19.181 102.022 25.308
201703 19.933 102.022 26.300
201706 21.164 102.752 27.726
201709 22.544 103.279 29.383
201712 23.771 103.793 30.829
201803 25.595 103.962 33.140
201806 27.851 104.875 35.748
201809 30.079 105.679 38.314
201812 31.993 105.912 40.662
201903 47.032 105.886 59.790
201906 48.627 106.742 61.323
201909 50.946 107.214 63.964
201912 54.948 107.766 68.635
202003 60.543 106.563 76.478
202006 60.317 107.498 75.530
202009 60.841 107.635 76.089
202012 65.447 108.296 81.350
202103 67.578 108.360 83.949
202106 68.525 108.928 84.681
202109 70.367 110.338 85.846
202112 75.089 112.486 89.858
202203 76.882 114.825 90.129
202206 78.555 118.384 89.322
202209 80.886 122.296 89.030
202212 85.590 126.365 91.174
202303 89.613 127.042 94.952
202306 91.275 129.407 94.945
202309 101.441 130.224 104.858
202312 99.680 131.912 101.719
202403 105.635 132.205 107.556
202406 106.126 132.716 107.641
202409 108.052 132.304 109.935
202412 117.327 132.987 118.759
202503 113.659 132.825 115.187
202506 113.369 133.699 114.142
202509 104.400 133.480 105.284
202512 109.133 133.380 110.139
202603 116.766 133.550 117.693
202606 121.709 134.610 121.709

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Swedish Orphan Biovitrum AB (CHIX:SOBIS) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of kr437.10 is trading 17.6% above its estimated GF Value™ of kr371.59. GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.

Key valuation signals for CHIX:SOBIS:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: kr371.59 vs. price of kr437.10 (17.6% above fair value)
  • GF Score™: 89/100 with 5 warning signs

No single metric tells the full story. See the CHIX:SOBIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
89GF Score

Get the complete analysis for CHIX:SOBIS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr437.10
Price
kr371.59
GF Value